Led · Equity · Dec 2022

ArenaCX is a tech-powered marketplace platform for business process outsourcing (BPO) led by CEO Alan Pendleton and based in Raleigh, NC. It curates and vets more than 100 BPO partners to supply outsourced talent across customer service, sales & marketing, accounting & bookkeeping, HR & recruiting, and administrative/back-office services. The platform uses data and industry expertise to provide an enterprise-level outsourcing RFP experience for companies of all sizes. In December 2022 the company raised $4.2M in funding. The round was led by Eagle Ventures, Sovereign's Capital, Beyond Capital and Triangle Tweener Fund. ArenaCX intends to use the funds to accelerate growth. ArenaCX, based in Raleigh, N.C., operates a customer service marketplace delivering on-demand support to businesses. Led by CEO Doc Shufelt, the company provides a network of integrated contact centers that enable businesses to access the amount of support they need on demand. Its management software dynamically matches support volume with trained agents, giving companies flexibility to scale customer service teams up or down and reducing time and money spent on hiring, training, and scheduling. The platform plugs into a business' existing customer service software suite and uses machine learning to categorize, prioritize, and assign customer support tickets. ArenaCX's software includes native forecasting capabilities and dashboarding that give support leaders control over their operations. The company plans to use new capital to further enhance its software platform, including integrations with more customer support software providers.

Led · Seed · Nov 2021

Splashlight Studios is a Dubai, UAE-based e-commerce digital solutions provider founded in 2020 by CEO Kartik Jobanputra. The company operates at the intersection of fashion and technology to help both emerging and established brands enter or expand in e-commerce. It offers end-to-end services including product shoots, campaign shoots, English and Arabic content, videos, and annual content calendars. Splashlight says it will use new funding to expand operations and accelerate development efforts. The company is also looking to expand into aggregation to reduce go-to-market time for young and legacy brands moving into digital.

Participated · Series C · Apr 2017

ALung Technologies develops the Hemolung Respiratory Assist System (RAS), a minimally invasive artificial lung that removes carbon dioxide independently of the lungs using a process called Respiratory Dialysis®. The company focuses on low‑flow extracorporeal carbon dioxide removal (ECCO2R) to treat patients with acute respiratory failure. The Hemolung RAS has been used to treat hundreds of patients outside the United States since 2013 and received FDA Expedited Access Pathway designation in 2015. ALung plans to use new funding to support a U.S.‑based pivotal clinical trial aimed at FDA approval and broader availability in the United States. The company is privately held and headquartered in Pittsburgh; it was founded in 1997. The recent financing strengthens clinical and commercialization plans while adding strategic partners to its board and advisory ranks. ALung Technologies is a privately held Pittsburgh-based developer and manufacturer of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies, notably the Hemolung RAS which uses a Respiratory Dialysis® process. The Hemolung RAS is positioned as a dialysis-like alternative or supplement to mechanical ventilation for acute respiratory failure, with applications in ARDS and COPD. The company reports CE mark clearance in 2013, global clinical adoption at leading centers, and that hundreds of patients have been treated with the technology. ALung is pursuing a share of the estimated $6 billion acute respiratory failure market. The company plans to use recent financing to support continued commercialization and to complete work required to obtain IDE approval for a U.S.-based clinical trial following its Expedited Access Pathway (EAP) designation. ALung was founded in 1997 and is backed by individual investors and venture firms named in its filings. ALung Technologies develops and manufactures the Hemolung Respiratory Assist System (RAS), a low‑flow, minimally invasive extracorporeal carbon dioxide removal (ECCO2R) device. The Hemolung provides Respiratory Dialysis® as an alternative or supplement to mechanical ventilation with indications including acute exacerbation of COPD and ARDS. The device was tested at 43 hospitals in 13 countries and following a successful clinical trial in Germany received regulatory clearances in Europe and Canada. ALung initiated a controlled launch in mid‑2013 and has accelerated commercial roll‑out in Germany, the UK, France, Canada, and Australia. The Hemolung RAS is currently approved in 29 countries across Europe, the Middle East, and Asia‑Pacific. The company says it will use new financing to accelerate global commercialization of the technology. ALung Technologies develops extracorporeal respiratory assist devices, principally the Hemolung Respiratory Assist System (RAS), a dialysis-like extracorporeal carbon dioxide removal (ECCO2R) system. The Hemolung RAS provides Respiratory Dialysis® as a simple, minimally invasive alternative or supplement to mechanical ventilation and has indications for ARDS and acute exacerbation of COPD. The device is approved for sale in Europe and Canada, and ALung has established direct commercial operations in Germany, France, and the United Kingdom while entering additional markets through distribution partners. The company intends to use new capital to support global commercialization and to further develop next-generation products and platform technologies for less-invasive extracorporeal lung support. To date ALung has raised $56 million in equity capital, and the recent financing will primarily support the global launch of the Hemolung RAS. ALung's lead product, HemoLung, is an extracorporeal artificial lung that removes carbon dioxide from blood while infusing oxygen via a catheter into the femoral or jugular vein. The device is intended for patients with acute respiratory failure to help them avoid mechanical ventilation. Four months after receiving CE Mark approval, ALung is commercializing HemoLung in Germany, France, the UK and Canada and plans sales in Canada and Australia. The company has set up 10 reference centers, is hiring clinical specialists and support staff, and is seeking distributors in Europe, Canada and Australia. ALung estimates a patient population of about 900,000 and a market opportunity of roughly $4.6 billion. The company was started in 1997 by Dr. Brack Hattler and Bill Federspiel.

Led · Equity · Jul 2009

Medrobotics develops and markets the Flex Robotic System, a steerable and shapeable robotic scope that enables surgeons to navigate complex anatomy through a single, small entry point. The Flex System is described as the world’s first and only robotic surgical platform providing Scarfree™ access in otolaryngology and colorectal procedures and has received FDA clearances for ENT and colorectal uses. The system was also cleared for robot-assisted visualization in general surgical, gynecological and thoracic procedures in the U.S., and holds a CE mark. Medrobotics is pursuing expanded applications including transvaginal gynecologic procedures and single-port abdominal applications in general surgery, urology and gynecology. The company is privately funded and headquartered in Raynham, Massachusetts. It recently announced a $25 million venture debt investment commitment to support product development and manufacturing expansion. Medrobotics manufactures and markets the Flex® Robotic System, a minimally-invasive, robot-assisted platform that allows surgeons to access, visualize, and deliver instruments to anatomical locations that are hard to reach with traditional methods. The company is led by President & CEO Samuel F. Straface, Ph.D., and is based in Raynham, Massachusetts. Medrobotics received FDA clearance for the Flex® Robotic System in 2015 and the CE mark in 2014. It closed a $25M financing in which existing shareholders participated. The company intends to use the funds to expand commercial efforts for the Flex® Robotic System. No revenue or user metrics were disclosed in the article. Medrobotics Corporation is a privately-held surgical products company headquartered in Raynham, Massachusetts that develops the Flex System, a robot-assisted flexible endoscopic platform, and the Flex Retractor. The Flex System provides surgeons single-site access and visualization of hard-to-reach anatomical locations, while the Flex Retractor is designed to facilitate exposure in advanced transoral surgeries. This year the company received CE marks for both the Flex System and the Flex Retractor and has met applicable FDA requirements to distribute the Flex Retractor in the U.S.; the Flex System is not currently cleared for sale in the U.S. Medrobotics closed a $20 million preferred stock financing with participation from existing shareholders to extend its runway. Proceeds will be used to support commercial launches in Europe and to prepare for FDA clearance and broader commercialization in the United States and other global markets. The company positions its products as affordable options for minimally invasive surgery that can reduce hospital stays, costs, and recovery times. Medrobotics is a privately-held surgical products company headquartered in Raynham, Massachusetts that develops and commercializes the Flex® System, a robot-assisted flexible endoscopic platform. The Flex® System received the CE mark and is designed to provide single-site access and visualization of hard-to-reach anatomical locations, enabling surgeons to navigate around anatomical structures and deploy flexible instruments using onboard high-definition vision. The company’s 3mm wristed Flex® Instruments have also received the CE mark. Medrobotics says it will use financing proceeds for regulatory preparations and submissions and for anticipated commercial launches in Europe and the United States. The platform aims to expand minimally invasive options where conventional line-of-sight technologies are infeasible or sub-optimal, potentially reducing hospital stays and recovery times. These products are not currently approved for sale in the U.S. Medrobotics Corporation, based in Raynham, Massachusetts, is developing and commercializing the Flex™ Robotic System. The Flex™ Robotic System is a robotic-assist platform that enables surgeons to gain single-site access and visualization to difficult-to-access anatomical locations. The system provides a precise and stable platform for enhanced visualization and enables two-handed dexterity with compatible third-party instruments having tactile feedback. The company is privately held and is preparing anticipated commercial launches in Europe and the United States. To support those launches, Medrobotics closed up to $10 Million in new debt financing.